Results 31 to 40 of about 4,863 (192)

Paraneoplastic thrombocytosis in ovarian cancer [PDF]

, 2012
<p>Background: The mechanisms of paraneoplastic thrombocytosis in ovarian cancer and the role that platelets play in abetting cancer growth are unclear.</p> <p>Methods: We analyzed clinical data on 619 patients with epithelial ...
Akl EA, Alpa M. Nick, Angela F. Drew, Anil K. Sood, Bulent Ozpolat, Chad V. Pecot, Charles N. Landen, Diana Urbauer, Donald Lamkin, Edward H. Ahn, Erin R. King, Frances Balkwill, Francisca Gushiken, Gabriel Lopez-Berestein, Guillermo N. Armaiz-Pena, Hannah Gershenson, Hee Dong Han, Hernan G. Vasquez, Iain A. McNeish, Ibrahim Tekedereli, Jermaine Coward, Justin Bottsford-Miller, Katherine Collins, Koen DeGeest, Koji Matsuo, Mian M.K. Shahzad, Michael T. Deavers, Rajesha Rupaimoole, Rebecca L. Stone, Riess L, Rui Wang, Susan K. Lutgendorf, Vahid Afshar-Kharghan, Virginia K. Bond, Wah Chiu, Wei Hu   +35 more
core   +1 more source

Are patients with HHV-8 associated Castleman disease successfully treated with rituximab at risk of subsequently developing HHV-8 negative (idiopathic) Castleman disease?

European Journal of Case Reports in Internal Medicine, 2023
Introduction: Multicentric Castleman disease (MCD) is a lymphoproliferative disorder characterized by lymph node histopathology and systemic symptoms.
Gavin Ha, Kelsey Kwong, Bryce Tanaka, Yoshito Nishimura, Christina Chong   +4 more
doaj   +1 more source

Is immunosuppressive therapy an effective treatment for COVID-19? – literature review

Journal of Education, Health and Sport, 2023
Introduction: The disease caused by SARS-CoV-2 is associated with a dysregulated immune response and a generalized inflammatory response. Therefore, during the search for effective therapy, attention was paid to drugs affecting and stabilizing such a ...
Barbara Ostrowska, Kacper Kołodziejczyk, Justyna Branewska, Izabela Hop, Mikołaj Matysek, Anna Olszanicka, Jan Imioło, Anna Maciąg, Rafał Niemiec, Adam Galas   +9 more
doaj   +1 more source

The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review [PDF]

, 2016
Introduction: While the majority of the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors currently used for the therapy of metastatic renal cell carcinoma (mRCC) are small molecule agents inhibiting multiple ...
Aieta, Michele, Ascione, Ilaria, Bosso, Davide, Buonerba, Carlo, Caraglia, Michele, De Cobelli, Ottavio, De Placido, Sabino, Di Lorenzo, Giuseppe, Facchini, Gaetano, Ferro, Matteo, Lucarelli, Giuseppe, Pagliuca, Martina, Pignataro, Piero, Puglia, Livio, Rossetti, Sabrina, Sonpavde, Guru, Terracciano, Daniela   +16 more
core   +1 more source

Siltuximab for Multicentric Castleman Disease—Letter [PDF]

Clinical Cancer Research, 2015
We read with great interest the article by Deisseroth and colleagues ([1][1]) focusing on the recent global approval of the monoclonal IL6 antibody siltuximab for the treatment of patients with HHV-8-, HIV-negative multicentric Castleman disease (MCD).
Raphael, Teipel, Rainer, Ordemann, Ulrike, Proske, Frank, Dietrich, Marika, Mende, Gerhard, Ehninger, Frank, Kroschinsky, Uwe, Platzbecker   +7 more
openaire   +2 more sources

IL-6 promotes necrotic apoptosis of mouse microglia cell line BV2 [PDF]

Jichu yixue yu linchuang, 2023
Objective To explore the regulatory mechanism of microglia apoptosis in neuroinflammation. Methods LPS was used to establish mouse microglia cell line BV2 cells as a neuroinflammatory microglia model, IL-6 antagonist siltuximab was applied to ...
ZHENG Jianbin, WU Shaohua, HUANG Yujing
doaj   +1 more source

Long-term treatment outcome of Castleman’s disease: A real-world experience

Frontiers in Oncology, 2022
BackgroundCastleman disease (CD), classified as unicentric CD (UCD) or multicentric CD (MCD), is a rare non-neoplastic lymphoproliferative disorder of unknown origin.
Gi-June Min, Young-Woo Jeon, Tong Yoon Kim, Dae Hun Kwag, Jong Hyuk Lee, Joon Yeop Lee, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Hee-Je Kim, Chang-Ki Min, Jong Wook Lee, Seok-Goo Cho   +17 more
doaj   +1 more source

Episodic fevers and vasodilatory shock mimicking urosepsis in a patient with HIV-associated multicentric Castleman’s Disease: a case report [PDF]

, 2016
Background: Multicentric Castleman's disease (MCD) is a pre-malignancy that presents with lymphadenopathy and features of systemic inflammation. Human immunodeficiency virus (HIV)-associated MCD is associated with human herpesvirus-8 (HHV-8) infection ...
Frederick J. Lee, Roger Garsia, Sarah C. Sasson, Stephanie Anderson, Stephen Larsen, Wendy Cooper   +5 more
core   +1 more source

Siltuximab - A monoclonal antibody against the interleukin-6 receptor is not an ideal option for management of COVID-19

Current Medicine Research and Practice, 2021
The sudden outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which emerged in Wuhan city, China, has resulted in a global pandemic, posing a major health concern worldwide.
I Jerlin Michelle, S A Shevaani, Kiran Kumar Rathinam, Justin Jacob Abraham, Muhasaparur Ganesan Rajanandh, Thangavel Mahalingam Vijayakumar   +5 more
doaj   +1 more source

Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. [PDF]

, 2014
Metastatic prostate cancer is lethal and lacks effective strategies for prevention or treatment, requiring novel therapeutic approaches. Interleukin-6 (IL-6) is a cytokine that has been linked with prostate cancer pathogenesis by multiple studies ...
Abdulghani, Junaid, Alanen, Kalle, Gu, Lei, Hoang, David T., Huszar, Dennis, Leiby, Benjamin E., Liao, Zhiyong, Mirtti, Tuomas, Nevalainen, Marja T., Romero-Weaver, Ana L, Talati, Pooja, Vogiatzi, Paraskevi, Zinda, Michael   +12 more
core   +2 more sources